Business
DECN Updates on Its Corona Virus Testing Product Genviro!(TM), With 200,000 Kits to Be Provided in USA & EU Prior to the Summer, 12 Month Forecast Updated to 480mm
DECN Updates on Its Corona Virus Testing Product Genviro!(TM), With 200,000 Kits to Be Provided in USA & EU Prior to the Summer, 12 Month Forecast Updated to 480mm.
About this update from Decision Diagnostics Corp
[{"type":"text","content":"Emergency Waiver in Progress With U.S. FDA for Use in Entities That Employ Staff Professionals, Wholesale Price to Be $6.95, Walk-In Patient Cost Expected to Be $29.95LOS ANGELES, CA / ACCESSWIRE / March 16, 2020 / Decision Diagnostics Corp. (OTC PINK:DECN) is an 18-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, its GenAccord! systems for the uninsured and under-insured, its GenChoice! ("Ladybug") test strip now in the later stages of FDA 510(k) prosecution, and its GenUltimate! Precis products manufactured for International markets.Today, DECN announces in this first of four releases expected in the next 14 days, further details of our revolutionary Coronavirus (Covid19) screening test GenViro!™. Our product, introduced to the world only 14 days ago has entered its crucial development stage. We are awaiting release of blood samples from previously infected people in Daegu, Korea, so that we can complete testing and make a final report to the U.S. FDA so that we may secure our Emergency Waiver. In the meantime, all other requests made by the FDA will be met this week and next. Further, we will engage in the EU with administrators of the ISO standard CE regulatory process this week. Only two diagnostic methodologies have been approved in the EU, none with the cost effectiveness or promise of GenViro! Our plan is designed to bring at least 100,000 of our kits to market in the USA and Canada, and another 100,000 in Europe, during the month of May 2020.Although the overall goal of our marketing plan for GenViro!™ is to sell the product directly to consumers for self-testing. Our initial efforts will be to provide overall verification of the GenViro!TM efficacy by working directly through organizations that regularly employ licensed medical technologists, or nurses (chain pharmacies, nursing home chains, and walk-in clinics). Our GenViro!™ will allow for the administration of the Covid-19 test through a "finger-stick," producing results in less than one-minute.Keith Berman, CEO of DECN commented, "We plan a total of three additional releases in the coming ...